Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106.1 USD | +0.47% | +0.18% | -3.55% |
04-29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
04-26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.55% | 184B | |
-0.69% | 109B | |
-2.11% | 68.37B | |
+4.71% | 51.56B | |
+9.52% | 44.69B | |
+4.37% | 41.49B | |
+2.64% | 26.75B | |
+4.23% | 26.7B | |
+15.38% | 25.68B | |
-0.52% | 24.8B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Abbott Laboratories : Morgan Stanley Adjusts Abbott Laboratories PT to $136 From $126, Maintains Overweight Rating